CORT vs SYRE โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
CORT Captures Institutional Edge (3โ1 Pillars ยท 7โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Corcept Therapeutics Inc. (CORT) driven by superior Valuation, Growth & Margin, Options & Structure while SYRE counters with relative strength in Momentum & Technical. Fundamentally, CORT trades at 14.6x Forward P/E with 11.5% operating margin (+64.0% YoY revenue) versus SYRE at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, CORT sits in CONSOLIDATION (10th %ile IV; Dealer Gamma Walls on Pro) against SYRE sits in UNCLASSIFIED (10th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | CORT | SYRE | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $8.1B | $9.8B | Larger Scale | SYRE |
| Trailing P/E Ratio Valuation | 55.4x | N/M | Lower Multiple | CORT |
| Forward P/E Ratio Valuation | 14.6x | N/M | Lower Multiple | CORT |
| Revenue Growth (YoY) Growth | +64.0% | +0.0% | Higher Growth | CORT |
| Operating Margin (TTM) Profitability | 11.5% | 0.0% | Higher Margin | CORT |
| Net Profit Margin Profitability | 16.8% | 0.0% | Higher Margin | CORT |
| Return on Equity (ROE) Capital Efficiency | 22.1% | -35.0% | Higher ROE | CORT |
| 52-Week Range Position Momentum | 42% ($29โ$126) | 88% ($22โ$111) | Stronger Trend | SYRE |
| Beta / 30D Volatility Risk Regime | 1.63ฮฒ ยท 85% Vol | 1.75ฮฒ ยท 59% Vol | Lower Realized Risk | SYRE |
| Unified Institutional Score Composite Signal | 50.7 / 100 (HOLD) | 44.4 / 100 (HOLD) | Higher Composite | CORT |